Registry for Allergen Immunotherapy in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Italian Registry of Allergy Immunotherapy (RIAIT) is a multicenter observational initiative aimed at collecting extensive data on Italian patients undergoing allergen immunotherapy (AIT) for respiratory allergies, such as rhinoconjunctivitis and asthma. The study evaluates the effectiveness and safety of AIT in real-life settings, assesses treatment decisions against international guidelines, and describes the long-term evolution of respiratory allergic diseases. It also aims to identify patient groups based on illness burden and management patterns while promoting standardized processes for diagnosis and treatment. Additionally, biomarker data will be analyzed to predict treatment responses and disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 1 year
* Confirmed diagnosis of allergic rhinoconjunctivitis and/or allergic asthma according to EAACI 2019 guidelines.
* Having been followed by the recruiting center for at least one month: this is considered necessary to establish that the patients are truly affected by allergic respiratory disease and are eligible for allergen-specific immunotherapy; in this period, screening tests are carried out to exclude and/or confirm concomitant diseases (comorbidities). In fact, according to the aforementioned EAACI guidelines, a patient can be defined as truly eligible for allergen-specific immunotherapy only after a preliminary phase in which the patient is treated with symptomatic therapy; this observation period allows a correct evaluation of the real adherence and response to therapy, as well as the identification and appropriate treatment of any comorbidity and the possible elimination of aggravating factors.
* Having received the prescription of any of the available AIT products in Italy, irrespectively of the selected allergens and the administration route and schedule.

Exclusion Criteria:

There will no be exclusion criteria, in order to allow a real-life vision of the characteristics of these patients eligible for or treated with allergen-specific immunotherapy.

Where it's running

• Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
  Rozzano, Milano, Italy Recruiting
• Azienda Ospedaliera Universitaria Istituto di Ricovero e Cura a Carattere Scientifico
  Florence, Italy Recruiting

Study contacts

• Principal investigator: Enrico Marco Heffler, MD, PhD — Humanitas Research Hospital IRCCS, Rozzano-Milan
• Study coordinator: Enrico Marco Heffler, MD, PhD
• Email: enrico.heffler@hunimed.eu
• Phone: +39 0282241

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Find the right dose of Exl-111 for people with allergic conditions

  This early test tries different single and repeated doses of Exl-111 in healthy adults to find a safe dose for future allergy treatment studies.

  Recruiting Phase 1 Excellergy Inc. · Adelaide, South Australia and 1 other locations · NCT07356713

• When IgE autoantibodies appear in newborns at risk for atopic dermatitis

  This study will test whether newborns with a family history of allergy already have self-reactive IgE antibodies at birth and whether those antibodies link to later atopic eczema.

  Recruiting Universitair Ziekenhuis Brussel · Jette, Brussels Capital · NCT07316465

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.